Compare DexCom, Inc. (DXCM) vs L3Harris Technologies Inc (LHX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs L3Harris Technologies Inc — how do they compare? DexCom, Inc. trades at $77.45 (market cap $28.06B), while L3Harris Technologies Inc trades at $284.07 (market cap $53.43B). The key difference: L3Harris Technologies Inc is the larger of the two by market cap, and L3Harris Technologies Inc pays a 1.74% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | LHX | |
|---|---|---|
Market Cap | $28.06B | $53.43B |
Sector | Health | Industrials |
52-Week High | $89.53 | $378.48 |
52-Week Low | $54.84 | $263.09 |
Enterprise Value | $27.03B | $64.20B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
LHX trades at $290.01, up 0.46% with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $21.87B in 2025 and strong analyst support with 75% buy ratings. Recent contract wins with the U.S. Space Force and Army highlight ongoing defense sector strength. Cash flow improved to $454M net in 2025, though debt levels remain elevated at 26.98% debt-to-asset ratio.
LHX presents a compelling value opportunity with a $367.50 consensus price target representing 27% upside. Defense spending tailwinds and record $40.7B backlog support growth, but investors face risks from execution challenges and geopolitical dependency. The stock's current valuation at 31.14 P/E appears reasonable given earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →
